Lonza Launches New Global Company Website
13 February 2012 – Lonza, one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries, announced today the launch of their new corporate website. The new website reflects a modern and innovative design to represent Lonza’s complete life science offering. The streamlined navigation provides customers, suppliers and shareholders with a simple and clear path to explore Lonza‘s Product and Service Offerings, Custom Manufacturing Capabilities and About Lonza Information.
“Our new website provides a significant improvement in our ability to digitally engage customers in a way that is meaningful and contributes to their everyday success”, said Shane Toothaker, Lonza’s Director of eBusiness. “Lonza’s portfolio has grown significantly over the last several years, and our goal was to present a unified approach online that demonstrates all that Lonza can offer the life science market, now and in the future.”
In a close collaboration with Isobar, a global communications agency, Lonza revised their digital strategy and launched a more customer-focused company website. The new digital strategy and platform allows the company to build stronger relationships with their customers with effective communication, improved services and marketing capabilities. The new website offers quick and easy access to essential information about the seven major markets that are served by Lonza: BioResearch, Pharma & Biotech, Nutrition, Microbial Control, Agriculture, Materials Science and Personal Care. In addition, the e-commerce platform for online purchases has been integrated into the designated product pages for a seamless shopping experience.
For further information, please visit the new www.lonza.com.
About Lonza
Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza is not subject to the SGX-ST’s continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2011, the company had sales of CHF 2.69 billion. Further information can be found at www.lonza.com.
